RSS feed

Publications by Odd Erik Johansen

138 publications found

Original articles

Marx N, Kolkailah AA, Rosenstock J, Johansen OE, Cooper ME, Alexander JH, Toto RD, Wanner C, Espeland MA, Mattheus M, Schnaidt S, Perkovic V, Gollop ND, McGuire DK (2024)
Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials
JAMA Cardiol, 9 (2), 134-143
DOI 10.1001/jamacardio.2023.4602, PubMed 38170502

Ard JD, Neeland IJ, Rothberg AE, Chilton RJ, de Luis D, Cohen SS, Johansen OE (2023)
The OPTIFAST total and partial meal replacement programme reduces cardiometabolic risk in adults with obesity: Secondary and exploratory analysis of the OPTIWIN study
Diabetes Obes Metab, 26 (3), 950-960
DOI 10.1111/dom.15392, PubMed 38073426

Shirin H, Neeland IJ, Ryan DH, de Luis D, Lecube A, Magos Z, Kenan Y, Amir R, Cohen DL, Johansen OE (2023)
Effects of an oral biodegradable device used for 12 weeks on weight reduction, cardiovascular risk factors, satiety, snacking, and meal size
Obes Pillars, 8, 100094
DOI 10.1016/j.obpill.2023.100094, PubMed 38125654

Johansen OE, Curti D, von Eynatten M, Rytz A, Lahiry A, Delodder F, Ufheil G, D'Urzo C, Orengo A, Thorne K, Lerea-Antes JS (2023)
Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial
Nutrients, 15 (12)
DOI 10.3390/nu15122752, PubMed 37375656

Ofstad AP, Brunborg C, Johansen OE, Mørkedal B, Fagerland MW, Laugsand LE, Gullestad LL, Dalen H (2023)
Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score
ESC Heart Fail, 10 (5), 2807-2815
DOI 10.1002/ehf2.14390, PubMed 37248650

Mohamed M, Zagury RL, Bhaskaran K, Neutel J, Mohd Yusof BN, Mooney L, Yeo L, Kirwan BA, Aprikian O, von Eynatten M, Johansen OE (2023)
A Randomized, Placebo-Controlled Crossover Study to Evaluate Postprandial Glucometabolic Effects of Mulberry Leaf Extract, Vitamin D, Chromium, and Fiber in People with Type 2 Diabetes
Diabetes Ther, 14 (4), 749-766
DOI 10.1007/s13300-023-01379-4, PubMed 36855010

Verhagen C, Janssen J, Minderhoud CA, van den Berg E, Wanner C, Passera A, Johansen OE, Biessels GJ (2022)
Chronic kidney disease and cognitive decline in patients with type 2 diabetes at elevated cardiovascular risk
J Diabetes Complications, 36 (10), 108303
DOI 10.1016/j.jdiacomp.2022.108303, PubMed 36116359

Verhagen C, Janssen J, Biessels GJ, Johansen OE, Exalto LG (2021)
Females with type 2 diabetes are at higher risk for accelerated cognitive decline than males: CAROLINA-COGNITION study
Nutr Metab Cardiovasc Dis, 32 (2), 355-364
DOI 10.1016/j.numecd.2021.10.013, PubMed 34895804

Vijayakumar VK, Mustafa T, Nore BK, Garatun-Tjeldstø KY, Næss Ø, Johansen OE, Aarli BB (2021)
Role of a Digital Clinical Decision-Support System in General Practitioners' Management of COPD in Norway
Int J Chron Obstruct Pulmon Dis, 16, 2327-2336
DOI 10.2147/COPD.S319753, PubMed 34413641

Ji Q, Ji L, Mu Y, Zhao J, Zinman B, Wanner C, George JT, Zwiener I, Ueki K, Yokote K, Ogawa W, Johansen OE (2021)
Effect of empagliflozin on cardiorenal outcomes and mortality according to body mass index: A subgroup analysis of the EMPA-REG OUTCOME trial with a focus on Asia
Diabetes Obes Metab, 23 (8), 1886-1891
DOI 10.1111/dom.14415, PubMed 33950573

Verma S, Mazer CD, Inzucchi SE, Wanner C, Ofstad AP, Johansen OE, Zwiener I, George JT, Butler J, Zinman B (2021)
Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME
Diabetes Obes Metab, 23 (5), 1173-1181
DOI 10.1111/dom.14326, PubMed 33502090

Biessels GJ, Verhagen C, Janssen J, van den Berg E, Wallenstein G, Zinman B, Espeland MA, Johansen OE (2021)
Effects of linagliptin vs glimepiride on cognitive performance in type 2 diabetes: results of the randomised double-blind, active-controlled CAROLINA-COGNITION study
Diabetologia, 64 (6), 1235-1245
DOI 10.1007/s00125-021-05393-8, PubMed 33559704

Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V, CARMELINA investigators (2021)
Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial
Clin Kidney J, 14 (1), 226-236
DOI 10.1093/ckj/sfaa225, PubMed 33564423

Espeland MA, Pratley RE, Rosenstock J, Kadowaki T, Seino Y, Zinman B, Marx N, McGuire DK, Andersen KR, Mattheus M, Keller A, Weber M, Johansen OE (2020)
Cardiovascular outcomes and safety with linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulphonylurea glimepiride in older people with type 2 diabetes: A subgroup analysis of the randomized CAROLINA trial
Diabetes Obes Metab, 23 (2), 569-580
DOI 10.1111/dom.14254, PubMed 33185002

McGuire DK, Zinman B, Inzucchi SE, Wanner C, Fitchett D, Anker SD, Pocock S, Kaspers S, George JT, von Eynatten M, Johansen OE, Jamal W, Mattheus M, Elsasser U, Hantel S, Lund SS (2020)
Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial
Lancet Diabetes Endocrinol, 8 (12), 949-959
DOI 10.1016/S2213-8587(20)30344-2, PubMed 33217335

Inzucchi SE, Davies MJ, Khunti K, Trivedi P, George JT, Zwiener I, Johansen OE, Sattar N (2020)
Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes
Diabetes Obes Metab, 23 (2), 425-433
DOI 10.1111/dom.14234, PubMed 33084149

Neeland IJ, Eliasson B, Kasai T, Marx N, Zinman B, Inzucchi SE, Wanner C, Zwiener I, Wojeck BS, Yaggi HK, Johansen OE, EMPA-REG OUTCOME Investigators (2020)
The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Diabetes Care, 43 (12), 3007-3015
DOI 10.2337/dc20-1096, PubMed 33004464

Verhagen C, Janssen J, Exalto LG, van den Berg E, Johansen OE, Biessels GJ (2020)
Diabetes-specific dementia risk score (DSDRS) predicts cognitive performance in patients with type 2 diabetes at high cardio-renal risk
J Diabetes Complications, 34 (10), 107674
DOI 10.1016/j.jdiacomp.2020.107674, PubMed 32723590

Kadowaki T, Wang G, Rosenstock J, Yabe D, Peng Y, Kanasaki K, Mu Y, Mattheus M, Keller A, Okamura T, Johansen OE, Marx N (2020)
Effect of linagliptin, a dipeptidyl peptidase-4 inhibitor, compared with the sulfonylurea glimepiride on cardiovascular outcomes in Asians with type 2 diabetes: subgroup analysis of the randomized CAROLINA® trial
Diabetol Int, 12 (1), 87-100
DOI 10.1007/s13340-020-00447-5, PubMed 33479584

Durheim MT, Hoffmann-Vold AM, Eagan TM, Hovden AO, Lund MB, Bjerke G, Birring SS, Jonassen TM, Johansen OE, Sjåheim T (2020)
ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
BMJ Open Respir Res, 7 (1)
DOI 10.1136/bmjresp-2020-000598, PubMed 32576559

Perkovic V, Toto R, Cooper ME, Mann JFE, Rosenstock J, McGuire DK, Kahn SE, Marx N, Alexander JH, Zinman B, Pfarr E, Schnaidt S, Meinicke T, von Eynatten M, George JT, Johansen OE, Wanner C, CARMELINA investigators (2020)
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Diabetes Care, 43 (8), 1803-1812
DOI 10.2337/dc20-0279, PubMed 32444457

Cooper ME, Rosenstock J, Kadowaki T, Seino Y, Wanner C, Schnaidt S, Clark D, Johansen OE, CARMELINA investigators (2020)
Cardiovascular and kidney outcomes of linagliptin treatment in older people with type 2 diabetes and established cardiovascular disease and/or kidney disease: A prespecified subgroup analysis of the randomized, placebo-controlled CARMELINA® trial
Diabetes Obes Metab, 22 (7), 1062-1073
DOI 10.1111/dom.13995, PubMed 32037653

Fitchett D, Inzucchi SE, Wanner C, Mattheus M, George JT, Vedin O, Zinman B, Johansen OE (2020)
Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial
Eur Heart J, 41 (2), 209-217
DOI 10.1093/eurheartj/ehz621, PubMed 31504427

Langslet G, Zinman B, Wanner C, Hantel S, Espadero RM, Fitchett D, Johansen OE (2020)
Cardiovascular outcomes and LDL-cholesterol levels in EMPA-REG OUTCOME^®
Diab Vasc Dis Res, 17 (6), 1479164120975256
DOI 10.1177/1479164120975256, PubMed 33307785

Inagaki N, Yang W, Watada H, Ji L, Schnaidt S, Pfarr E, Okamura T, Johansen OE, George JT, von Eynatten M, Rosenstock J, Perkovic V, Wanner C, Cooper ME, Alexander JH, Komuro I, Nangaku M (2019)
Linagliptin and cardiorenal outcomes in Asians with type 2 diabetes mellitus and established cardiovascular and/or kidney disease: subgroup analysis of the randomized CARMELINA^® trial
Diabetol Int, 11 (2), 129-141
DOI 10.1007/s13340-019-00412-x, PubMed 32206483

Rosenstock J, Kahn SE, Johansen OE, Zinman B, Espeland MA, Woerle HJ, Pfarr E, Keller A, Mattheus M, Baanstra D, Meinicke T, George JT, von Eynatten M, McGuire DK, Marx N, CAROLINA Investigators (2019)
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial
JAMA, 322 (12), 1155-1166
DOI 10.1001/jama.2019.13772, PubMed 31536101

Biessels GJ, Verhagen C, Janssen J, van den Berg E, Zinman B, Rosenstock J, George JT, Passera A, Schnaidt S, Johansen OE, CARMELINA Investigators (2019)
Effect of Linagliptin on Cognitive Performance in Patients With Type 2 Diabetes and Cardiorenal Comorbidities: The CARMELINA Randomized Trial
Diabetes Care, 42 (10), 1930-1938
DOI 10.2337/dc19-0783, PubMed 31399442

Le LAK, Johannessen A, Hardie JA, Johansen OE, Gulsvik A, Vikse BE, Bakke P (2019)
Prevalence and prognostic ability of the GOLD 2017 classification compared to the GOLD 2011 classification in a Norwegian COPD cohort
Int J Chron Obstruct Pulmon Dis, 14, 1639-1655
DOI 10.2147/COPD.S194019, PubMed 31413559

Groeneveld ON, van den Berg E, Johansen OE, Schnaidt S, Hermansson K, Zinman B, Espeland MA, Biessels GJ (2019)
Oxidative stress and endothelial dysfunction are associated with reduced cognition in type 2 diabetes
Diab Vasc Dis Res, 16 (6), 577-581
DOI 10.1177/1479164119848093, PubMed 31068001

Ofstad AP, Sommer C, Birkeland KI, Bjørgaas MR, Gran JM, Gulseth HL, Johansen OE (2019)
Comparison of the associations between non-traditional and traditional indices of adiposity and cardiovascular mortality: an observational study of one million person-years of follow-up
Int J Obes (Lond), 43 (5), 1082-1092
DOI 10.1038/s41366-019-0353-9, PubMed 30926954

McGuire DK, Marx N, Johansen OE, Inzucchi SE, Rosenstock J, George JT (2019)
FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later
Diabetes Obes Metab, 21 (5), 1073-1078
DOI 10.1111/dom.13645, PubMed 30690856

Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE, Sambevski S, Kaspers S, Pfarr E, George JT, Zinman B (2019)
Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial
Circulation, 139 (11), 1384-1395
DOI 10.1161/CIRCULATIONAHA.118.037778, PubMed 30586757

Arora S, Ofstad AP, Ulimoen GR, Birkeland KI, Endresen K, Gullestad L, Johansen OE (2019)
Asymptomatic coronary artery disease in a Norwegian cohort with type 2 diabetes: a prospective angiographic study with intravascular ultrasound evaluation
Cardiovasc Diabetol, 18 (1), 26
DOI 10.1186/s12933-019-0832-2, PubMed 30851727

McGuire DK, Alexander JH, Johansen OE, Perkovic V, Rosenstock J, Cooper ME, Wanner C, Kahn SE, Toto RD, Zinman B, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, Marx N, CARMELINA Investigators (2019)
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Circulation, 139 (3), 351-361
DOI 10.1161/CIRCULATIONAHA.118.038352, PubMed 30586723

Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, Alexander JH, Pencina M, Toto RD, Wanner C, Zinman B, Woerle HJ, Baanstra D, Pfarr E, Schnaidt S, Meinicke T, George JT, von Eynatten M, McGuire DK, CARMELINA Investigators (2019)
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial
JAMA, 321 (1), 69-79
DOI 10.1001/jama.2018.18269, PubMed 30418475

Heier M, Ofstad AP, Borja MS, Brunborg C, Endresen K, Gullestad L, Birkeland KI, Johansen OE, Oda MN (2018)
High-density lipoprotein function is associated with atherosclerotic burden and cardiovascular outcomes in type 2 diabetes
Atherosclerosis, 282, 183-187
DOI 10.1016/j.atherosclerosis.2018.07.005, PubMed 30017177

Zinman B, Inzucchi SE, Wanner C, Hehnke U, George JT, Johansen OE, Fitchett D, EMPA-REG OUTCOME® investigators (2018)
Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME®
Diabetologia, 61 (7), 1522-1527
DOI 10.1007/s00125-018-4630-2, PubMed 29713728

Fitchett D, Butler J, van de Borne P, Zinman B, Lachin JM, Wanner C, Woerle HJ, Hantel S, George JT, Johansen OE, Inzucchi SE, EMPA-REG OUTCOME® trial investigators (2018)
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial
Eur Heart J, 39 (5), 363-370
DOI 10.1093/eurheartj/ehx511, PubMed 29020355

Biessels GJ, Janssen J, van den Berg E, Zinman B, Espeland MA, Mattheus M, Johansen OE, CAROLINA® investigators (2018)
Rationale and design of the CAROLINA® - cognition substudy: a randomised controlled trial on cognitive outcomes of linagliptin versus glimepiride in patients with type 2 diabetes mellitus
BMC Neurol, 18 (1), 7
DOI 10.1186/s12883-018-1014-7, PubMed 29334906

Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberg K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM (2017)
How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial
Diabetes Care, 41 (2), 356-363
DOI 10.2337/dc17-1096, PubMed 29203583

Cherney DZI, Cooper ME, Tikkanen I, Pfarr E, Johansen OE, Woerle HJ, Broedl UC, Lund SS (2017)
Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin
Kidney Int, 93 (1), 231-244
DOI 10.1016/j.kint.2017.06.017, PubMed 28860019

Chilton R, Tikkanen I, Hehnke U, Woerle HJ, Johansen OE (2017)
Impact of empagliflozin on blood pressure in dipper and non-dipper patients with type 2 diabetes mellitus and hypertension
Diabetes Obes Metab, 19 (11), 1620-1624
DOI 10.1111/dom.12962, PubMed 28387058

Ofstad AP, Ulimoen GR, Orvik E, Birkeland KI, Gullestad LL, Fagerland MW, Johansen OE (2017)
Long-term follow-up of a hospital-based, multi-intervention programme in type 2 diabetes mellitus: impact on cardiovascular events and death
J Int Med Res, 45 (5), 1535-1552
DOI 10.1177/0300060517707674, PubMed 28627980

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Fitchett D, Kohler S, Mattheus M, Woerle HJ, Broedl UC, Johansen OE, Albers GW, Diener HC, EMPA-REG OUTCOME Investigators (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) (2017)
Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
Stroke, 48 (5), 1218-1225
DOI 10.1161/STROKEAHA.116.015756, PubMed 28386035

Mancia G, Cannon CP, Tikkanen I, Zeller C, Ley L, Woerle HJ, Broedl UC, Johansen OE (2016)
Impact of Empagliflozin on Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension by Background Antihypertensive Medication
Hypertension, 68 (6), 1355-1364
DOI 10.1161/HYPERTENSIONAHA.116.07703, PubMed 27977392

Wanner C, Inzucchi SE, Lachin JM, Fitchett D, von Eynatten M, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, Zinman B, EMPA-REG OUTCOME Investigators (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
N Engl J Med, 375 (4), 323-34
DOI 10.1056/NEJMoa1515920, PubMed 27299675

Neeland IJ, McGuire DK, Chilton R, Crowe S, Lund SS, Woerle HJ, Broedl UC, Johansen OE (2016)
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus
Diab Vasc Dis Res, 13 (2), 119-26
DOI 10.1177/1479164115616901, PubMed 26873905

Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME® trial investigators (2016)
Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
Eur Heart J, 37 (19), 1526-34
DOI 10.1093/eurheartj/ehv728, PubMed 26819227

Lehrke M, Leiter LA, Hehnke U, Thiemann S, Bhandari A, Meinicke T, Johansen OE (2016)
Safety and efficacy of linagliptin in patients with type 2 diabetes mellitus and coronary artery disease: Analysis of pooled events from 19 clinical trials
J Diabetes Complications, 30 (7), 1378-84
DOI 10.1016/j.jdiacomp.2016.06.015, PubMed 27396241

Neeland IJ, McGuire DK, Eliasson B, Ridderstråle M, Zeller C, Woerle HJ, Broedl UC, Johansen OE (2015)
Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
Diabetes Ther, 6 (4), 635-642
DOI 10.1007/s13300-015-0146-7, PubMed 26608511

Ulimoen GR, Ofstad AP, Endresen K, Gullestad L, Johansen OE, Borthne A (2015)
Low-dose CT coronary angiography for assessment of coronary artery disease in patients with type 2 diabetes--a cross-sectional study
BMC Cardiovasc Disord, 15, 147
DOI 10.1186/s12872-015-0143-9, PubMed 26573616

Perkins BA, Cherney DZ, Soleymanlou N, Lee JA, Partridge H, Tschirhart H, Zinman B, Mazze R, Fagan N, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2015)
Diurnal Glycemic Patterns during an 8-Week Open-Label Proof-of-Concept Trial of Empagliflozin in Type 1 Diabetes
PLoS One, 10 (11), e0141085
DOI 10.1371/journal.pone.0141085, PubMed 26544192

Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE (2015)
Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis
Can J Diabetes, 40 (1), 50-7
DOI 10.1016/j.jcjd.2015.06.010, PubMed 26474870

Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Broedl UC, Johansen OE (2015)
Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes
Diabetes Obes Metab, 17 (12), 1180-93
DOI 10.1111/dom.12572, PubMed 26343814

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE, EMPA-REG OUTCOME Investigators (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
N Engl J Med, 373 (22), 2117-28
DOI 10.1056/NEJMoa1504720, PubMed 26378978

Pieber TR, Famulla S, Eilbracht J, Cescutti J, Soleymanlou N, Johansen OE, Woerle HJ, Broedl UC, Kaspers S (2015)
Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1)
Diabetes Obes Metab, 17 (10), 928-35
DOI 10.1111/dom.12494, PubMed 26080652

Rosenstock J, Marx N, Neubacher D, Seck T, Patel S, Woerle HJ, Johansen OE (2015)
Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events
Cardiovasc Diabetol, 14, 57
DOI 10.1186/s12933-015-0215-2, PubMed 25990013

Marx N, Rosenstock J, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Espeland MA, Bluhmki E, Mattheus M, Ryckaert B, Patel S, Johansen OE, Woerle HJ (2015)
Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®)
Diab Vasc Dis Res, 12 (3), 164-74
DOI 10.1177/1479164115570301, PubMed 25780262

Ofstad AP, Urheim S, Dalen H, Orvik E, Birkeland KI, Gullestad L, W Fagerland M, Johansen OE, Aakhus S (2015)
Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls
J Diabetes, 7 (6), 779-90
DOI 10.1111/1753-0407.12239, PubMed 25350248

Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE (2015)
SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials
Diab Vasc Dis Res, 12 (2), 90-100
DOI 10.1177/1479164114559852, PubMed 25589482

Lehrke M, Marx N, Patel S, Seck T, Crowe S, Cheng K, von Eynatten M, Johansen OE (2014)
Safety and Tolerability of Linagliptin in Patients With Type 2 Diabetes: A Comprehensive Pooled Analysis of 22 Placebo-controlled Studies
Clin Ther, 36 (8), 1130-46
DOI 10.1016/j.clinthera.2014.06.008, PubMed 25015594

Zinman B, Inzucchi SE, Lachin JM, Wanner C, Ferrari R, Fitchett D, Bluhmki E, Hantel S, Kempthorne-Rawson J, Newman J, Johansen OE, Woerle HJ, Broedl UC (2014)
Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME™)
Cardiovasc Diabetol, 13, 102
DOI 10.1186/1475-2840-13-102, PubMed 24943000

Ofstad AP, Johansen OE, Gullestad L, Birkeland KI, Orvik E, Fagerland MW, Urheim S, Aakhus S (2014)
Neutral impact on systolic and diastolic cardiac function of 2 years of intensified multi-intervention in type 2 diabetes: the randomized controlled Asker and Bærum Cardiovascular Diabetes (ABCD) study
Am Heart J, 168 (3), 280-288.e2
DOI 10.1016/j.ahj.2014.03.026, PubMed 25173538

Perkins BA, Cherney DZ, Partridge H, Soleymanlou N, Tschirhart H, Zinman B, Fagan NM, Kaspers S, Woerle HJ, Broedl UC, Johansen OE (2014)
Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial
Diabetes Care, 37 (5), 1480-3
DOI 10.2337/dc13-2338, PubMed 24595630

Cherney DZ, Perkins BA, Soleymanlou N, Har R, Fagan N, Johansen OE, Woerle HJ, von Eynatten M, Broedl UC (2014)
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
Cardiovasc Diabetol, 13, 28
DOI 10.1186/1475-2840-13-28, PubMed 24475922

Gerner T, Johansen OE, Olufsen M, Torjesen PA, Tveit A (2014)
The post-prandial pattern of gut hormones is related to magnitude of weight-loss following gastric bypass surgery: a case-control study
Scand J Clin Lab Invest, 74 (3), 213-8
DOI 10.3109/00365513.2013.877594, PubMed 24472033

Cherney DZ, Perkins BA, Soleymanlou N, Maione M, Lai V, Lee A, Fagan NM, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M (2013)
Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus
Circulation, 129 (5), 587-97
DOI 10.1161/CIRCULATIONAHA.113.005081, PubMed 24334175

Ofstad AP, Gullestad L, Orvik E, Aakhus S, Endresen K, Ueland T, Aukrust P, Fagerland MW, Birkeland KI, Johansen OE (2013)
Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study
Cardiovasc Diabetol, 12, 126
DOI 10.1186/1475-2840-12-126, PubMed 23987834

Ueland T, Aukrust P, Aakhus S, Smith C, Endresen K, Birkeland KI, Gullestad L, Johansen OE (2012)
Activin A and cardiovascular disease in type 2 diabetes mellitus
Diab Vasc Dis Res, 9 (3), 234-7
DOI 10.1177/1479164111431171, PubMed 22234949

Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ (2012)
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme
Cardiovasc Diabetol, 11, 3
DOI 10.1186/1475-2840-11-3, PubMed 22234149

Haukeland JW, Dahl TB, Yndestad A, Gladhaug IP, Løberg EM, Haaland T, Konopski Z, Wium C, Aasheim ET, Johansen OE, Aukrust P, Halvorsen B, Birkeland KI (2011)
Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies
Eur J Endocrinol, 166 (3), 503-10
DOI 10.1530/EJE-11-0864, PubMed 22170794

Sørensen M, Johansen OE (2010)
Idiopathic reactive hypoglycaemia - prevalence and effect of fibre on glucose excursions
Scand J Clin Lab Invest, 70 (6), 385-91
DOI 10.3109/00365513.2010.491869, PubMed 20509823

Hallén J, Johansen OE, Birkeland KI, Gullestad L, Aakhus S, Endresen K, Tjora S, Jaffe AS, Atar D (2010)
Determinants and prognostic implications of cardiac troponin T measured by a sensitive assay in type 2 diabetes mellitus
Cardiovasc Diabetol, 9, 52
DOI 10.1186/1475-2840-9-52, PubMed 20843304

Kontny F, Risanger T, Bye A, Arnesen Ø, Johansen OE, TELMIMORE Study Investigators (2010)
Effects of telmisartan on office and 24-hour ambulatory blood pressure: an observational study in hypertensive patients managed in primary care
Vasc Health Risk Manag, 6, 31-8
DOI 10.2147/vhrm.s9122, PubMed 20191081

Johansen OE, Birkeland KI, Jørgensen AP, Orvik E, Sørgård B, Torjussen BR, Ueland T, Aukrust P, Gullestad L (2009)
Diabetic foot ulcer burden may be modified by high-dose atorvastatin: A 6-month randomized controlled pilot trial
J Diabetes, 1 (3), 182-7
DOI 10.1111/j.1753-0407.2009.00031.x, PubMed 20923537

Johansen OE, Vanberg PJ, Kilhovd BK, Jørgensen AP (2009)
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Vasc Health Risk Manag, 5 (1), 121-8
PubMed 19436668

Johansen OE, Brustad E, Enger S, Tveit A (2008)
Prevalence of abnormal glucose metabolism in atrial fibrillation: a case control study in 75-year old subjects
Cardiovasc Diabetol, 7, 28
DOI 10.1186/1475-2840-7-28, PubMed 18822173

Johansen OE, Gullestad L, Blaasaas KG, Orvik E, Birkeland KI (2007)
Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial
Diabet Med, 24 (9), 1019-27
DOI 10.1111/j.1464-5491.2007.02198.x, PubMed 17509068

Johansen OE, Birkeland KI, Orvik E, Flesland Ø, Wergeland R, Ueland T, Smith C, Endresen K, Aukrust P, Gullestad L (2007)
Inflammation and coronary angiography in asymptomatic type 2 diabetic subjects
Scand J Clin Lab Invest, 67 (3), 306-16
DOI 10.1080/00365510601045088, PubMed 17454845

Johansen OE, Jørgensen AP (2006)
[Glitazone treatment of type 2 diabetes mellitus]
Tidsskr Nor Laegeforen, 126 (15), 1928-30
PubMed 16915317

Johansen OE, Birkeland KI, Brustad E, Aaser E, Lindahl AK, Midha R, Ueland T, Aukrust P, Gullestad L (2006)
Undiagnosed dysglycaemia and inflammation in cardiovascular disease
Eur J Clin Invest, 36 (8), 544-51
DOI 10.1111/j.1365-2362.2006.01679.x, PubMed 16893376

Starkopf J, Hegna S, Johansen OE, Munch-Ellingsen J, Mjøs OD, Ytrehus K (2006)
In vivo chronic carvedilol treatment in rats attenuates ex vivo regional infarction of the heart
Scand Cardiovasc J, 40 (4), 240-7
DOI 10.1080/14017430600806286, PubMed 16914417

Review articles

Darsalia V, Johansen OE, Lietzau G, Nyström T, Klein T, Patrone C (2019)
Dipeptidyl Peptidase-4 Inhibitors for the Potential Treatment of Brain Disorders; A Mini-Review With Special Focus on Linagliptin and Stroke
Front Neurol, 10, 493
DOI 10.3389/fneur.2019.00493, PubMed 31139140

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions
Heart Fail Rev, 23 (3), 303-323
DOI 10.1007/s10741-018-9685-0, PubMed 29516230

Andresen K, Atar D, Gjertsen E, Ghanima W, Roseth S, Johansen OE (2018)
Mechanisms of action and clinical use of specific reversal agents for non-vitamin K antagonist oral anticoagulants
Scand Cardiovasc J, 52 (3), 156-162
DOI 10.1080/14017431.2018.1453613, PubMed 29569500

Tikkanen I, Chilton R, Johansen OE (2016)
Potential role of sodium glucose cotransporter 2 inhibitors in the treatment of hypertension
Curr Opin Nephrol Hypertens, 25 (2), 81-6
DOI 10.1097/MNH.0000000000000199, PubMed 26808705

Rosenstock J, Marx N, Kahn SE, Zinman B, Kastelein JJ, Lachin JM, Bluhmki E, Patel S, Johansen OE, Woerle HJ (2013)
Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial
Diab Vasc Dis Res, 10 (4), 289-301
DOI 10.1177/1479164112475102, PubMed 23449634

Johansen OE, Qvigstad E (2008)
Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg
Adv Ther, 25 (6), 525-51
DOI 10.1007/s12325-008-0070-6, PubMed 18568306

Johansen OE (2007)
Cardiovascular disease and type 2 diabetes mellitus: a multifaceted symbiosis
Scand J Clin Lab Invest, 67 (8), 786-800
DOI 10.1080/00365510701408558, PubMed 17852797

Johansen OE, Birkeland KI (2007)
Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review
Am J Cardiovasc Drugs, 7 (5), 319-35
DOI 10.2165/00129784-200707050-00002, PubMed 17953471

Johansen OE, Birkeland KI (2003)
Preventing macrovascular disease in patients with type 2 diabetes mellitus
Am J Cardiovasc Drugs, 3 (4), 283-97
DOI 10.2165/00129784-200303040-00007, PubMed 14728081

Other articles

Wanner C, Cooper ME, Johansen OE, Toto R, Rosenstock J, McGuire DK, Kahn SE, Pfarr E, Schnaidt S, von Eynatten M, George JT, Gollop ND, Marx N, Alexander JH, Zinman B, Perkovic V (2021)
Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial
Clin Kidney J, 14 (9), 2136
DOI 10.1093/ckj/sfab104, PubMed 34476096

Neeland IJ, Kasai T, Inzucchi SE, Wojeck BS, Yaggi HK, Johansen OE, EMPA-REG OUTCOME Investigators (2021)
Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015
Diabetes Care, 44 (6), e137-e138
DOI 10.2337/dci21-0009, PubMed 34016610

McGuire DK, Inzucchi SE, Johansen OE, Rosenstock J, George JT, Marx N (2021)
Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits
J Pharm Policy Pract, 14 (1), 35
DOI 10.1186/s40545-020-00295-3, PubMed 33858511

Janssen J, van den Berg E, Zinman B, Espeland MA, Geijselaers SLC, Mattheus M, Johansen OE, Biessels GJ (2019)
HbA_1c, Insulin Resistance, and β-Cell Function in Relation to Cognitive Function in Type 2 Diabetes: The CAROLINA Cognition Substudy
Diabetes Care, 42 (1), e1-e3
DOI 10.2337/DC18-0914, PubMed 30811335

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
Author's response to: letter to the editor
Heart Fail Rev, 23 (5), 819
DOI 10.1007/s10741-018-9728-6, PubMed 30043131

Neeland IJ, McGuire DK, Eliasson B, Ridderstråle M, Zeller C, Woerle HJ, Broedl UC, Johansen OE (2018)
Correction to: Comparison of Adipose Distribution Indices with Gold Standard Body Composition Assessments in the EMPA-REG H2H SU Trial: A Body Composition Sub-Study
Diabetes Ther, 9 (4), 1721
DOI 10.1007/s13300-018-0465-6, PubMed 29931507

Ofstad AP, Atar D, Gullestad L, Langslet G, Johansen OE (2018)
Response to the editor
Heart Fail Rev (in press)
DOI 10.1007/s10741-018-9723-y, PubMed 29968222

Fitchett D, Inzucchi SE, Lachin JM, Wanner C, van de Borne P, Mattheus M, Johansen OE, Woerle HJ, Broedl UC, George JT, Zinman B, EMPA-REG OUTCOME Investigators (2018)
Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease
J Am Coll Cardiol, 71 (3), 364-367
DOI 10.1016/j.jacc.2017.11.022, PubMed 29348030

Škrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZI (2017)
Erratum to: Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Diabetologia, 60 (6), 1159-1160
DOI 10.1007/s00125-017-4241-3, PubMed 28374067

Johansen OE (2015)
Interpretation of cardiovascular outcome trials in type 2 diabetes needs a multiaxial approach
World J Diabetes, 6 (9), 1092-6
DOI 10.4239/wjd.v6.i9.1092, PubMed 26265995

Cherney DZ, Perkins BA, Soleymanlou N, Xiao F, Zimpelmann J, Woerle HJ, Johansen OE, Broedl UC, von Eynatten M, Burns KD (2014)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
Kidney Int, 86 (5), 1057-8
DOI 10.1038/ki.2014.246, PubMed 25360497

Skrtić M, Yang GK, Perkins BA, Soleymanlou N, Lytvyn Y, von Eynatten M, Woerle HJ, Johansen OE, Broedl UC, Hach T, Silverman M, Cherney DZ (2014)
Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration
Diabetologia, 57 (12), 2599-602
DOI 10.1007/s00125-014-3396-4, PubMed 25280671

Johansen OE, Boehm BO, Grill V, Torjesen PA, Bhattacharya S, Patel S, Wetzel K, Woerle HJ (2014)
C-peptide levels in latent autoimmune diabetes in adults treated with linagliptin versus glimepiride: exploratory results from a 2-year double-blind, randomized, controlled study
Diabetes Care, 37 (1), e11-2
DOI 10.2337/dc13-1523, PubMed 24356601

Rosenstock J, Marx N, Johansen OE, Wörle HJ, CAROLINA Steering Committee (2013)
Cardiovascular effects of diabetes drugs: making the dark ages brighter with Carolina
Ann Intern Med, 158 (6), 499
DOI 10.7326/0003-4819-158-6-201303190-00017, PubMed 23553039

Johansen OE (2008)
[Urogenital problems and female Internet users]
Tidsskr Nor Laegeforen, 128 (24), 2845-6
PubMed 19092957

Johansen OE, Whitfield R (2008)
Exenatide may aggravate moderate diabetic renal impairment: a case report
Br J Clin Pharmacol, 66 (4), 568-9
DOI 10.1111/j.1365-2125.2008.03221.x, PubMed 18537959

Johansen OE, Bjurö T, Endresen K, Blaasaas KG, Birkeland K, Aakhus S, Gullestad L (2007)
Heart rate adjustments and analysis of recovery patterns of ST-segment depression in type 2 diabetes
Int J Cardiol, 127 (1), 129-32
DOI 10.1016/j.ijcard.2007.04.022, PubMed 17532067

Johansen OE (2007)
[Natural preparations against climacteric problems?]
Tidsskr Nor Laegeforen, 127 (6), 764-5
PubMed 17363992

Johansen OE, Birkeland KI (2005)
[Misleading about insulin administration to patients with diabetes]
Tidsskr Nor Laegeforen, 125 (16), 2247; author reply 2247
PubMed 16138161

Books

Johansen OE (2008)
Barns forestillinger om jorda som planet i verdensrommet
In Rapport, Telemarksforsking, Notodden, 02/2008, 22 bl.
BIBSYS 091827124, ISBN 82-7463-143-9

Johansen OE, Schaathun A, Streitlien Å (2004)
LærerIKT - en lærerik erfaring?
In Rapport, Telemarksforsking, Notodden, 03/2004, 122 bl.
BIBSYS 041605624, ISBN 82-7463-116-1

Johansen OE, Wiik L (2004)
Babilani - matematikk på en ny måte?
In Rapport, Telemarksforsking, Notodden, 08/2004, 37 bl.
BIBSYS 051154390, ISBN 82-7463-125-0

Johansen OE, Schaathun A (2004)
Enda mer lærerIKT?
In Rapport, Telemarksforsking, Notodden, 06/2004, 67, 22 bl.
BIBSYS 041846761, ISBN 82-7463-121-8

Johansen OE (2001)
Ingeniørutdanning med første studieår på Notodden, markedsundersøkelse
In Rapport, Telemarksforsking, Notodden, 01/01, 23 bl.
BIBSYS 020118244, ISBN 82-7463-062-9

Johansen OE, Larsen S (2001)
Noen kommentarer til undersøkelsen "Allmennlærerstudentenes fagprofil, sammenholdt med lærersituasjonen i grunnskolen"
In Notat, Telemarksforsking-Notodden, Notodden, 01/01, 5 bl.
BIBSYS 021926832, ISBN 82-7463-081-5

Johansen OE (2001)
Tiltak for kompetanseutvikling i Notodden
In Rapport, Telemarksforsking, Notodden, 18/00, 12 bl.
BIBSYS 011713429, ISBN 82-7463-061-0

Bjerketvedt DK, Johansen OE (2000)
Fra 'skur' til byggverk: tilbud om etablering av Statens kunnskaps-og utviklingssenter (SKUR) ved Høgskolen i Telemark
In Rapport, Telemarksforsking, Notodden, 03/00, 34 s.
BIBSYS 030938147, ISBN 82-7463-044-0

Johansen OE (2000)
Studentjubiléer som virkemiddel for stedsutvikling og studentrekruttering: prosjektidé og markedsundersøkelse
In Rapport, Telemarksforsking, Notodden, 04/00, 20 s.
BIBSYS 03093799x, ISBN 82-7463-045-9

Johansen OE (1990)
Rapport fra et 3-årig forsøk med forskingsstiftelse for pedagogisk forsking og utviklingsarbeid
In Rapport, Telemarksforsking, Notodden, 09/1990, 24, [24] bl.
BIBSYS 921598831

Johansen OE (1990)
Transportutdanning på Notodden
In Rapport, Telemarksforsking, Notodden, 01/90, 17 bl.
BIBSYS 921596286

Kirke- og undervisningsdepartementet, Johansen OE, Datasekretariatet (1989)
Innstilling om sentralt organ for vidareføring av oppgåver som var tillagt Datasekretariatet og som ikkje utan vidare kan overførast til andre organ: Frå eit utval oppnemnd av KUD oktober 1988 og avgitt 7. juli 1989
Oslo, 39s.2bl.
BIBSYS 990374211

Gange TN, Johansen OE (1988)
Forskningsbehov i skoleverket
In Rapport (Kommunaløkonomisk forskning. Nytt inntektssystemfor kommunene (prosjekt)), Rådet for forskning for samfunnsplanlegging., [Oslo], 30 bl.
BIBSYS 08010620x, ISBN 82-7437-007-4

Johansen OE (1987)
Laboratorieøvelser i fysikk 1: oppgaver for 1. halvårsenhet i fysikk/kjemi
[Telemark lærerhøyskole], [Notodden], 56 bl.
BIBSYS 940246732

Johansen OE (1987)
Laboratorieøvelser i fysikk 2: oppgaver for 2. halvårsenhet i fysikk/ kjemi
In Nota bile, Lærarhøgskolen., [Notodden], Nr 6-87, 29 bl.
BIBSYS 940287994

Johansen OE (1982)
Energikjeder, næringskjeder: arbeidsbok for 5. klasse
In Møt naturen, Tanum-Norli, Oslo, 45 s.
BIBSYS 970777973, ISBN 82-518-1601-7

Johansen OE (1982)
Programmering i BASIC: noen elementære oppgaver
In Nota bile, Lærarhøgskolen., [Notodden], 4/1982, [33] bl.
BIBSYS 882000993

Johansen OE (1981)
System, miljø og variabler: arbeidsbok for 4. klasse
In Møt naturen, Tanum-Norli, Oslo, 48 s.
BIBSYS 042199484, ISBN 82-518-1440-5

Johansen OE (1980)
Posisjon, bevegelse og populasjoner: arbeidsbok for 3. klasse
In Møt naturen, Tanum-Norli, Oslo, 35 s.
BIBSYS 990941353, ISBN 82-518-0966-5

Johansen OE (1979)
Naturfag på en ny måte?
Tanum-Norli, Oslo, 53 s.
BIBSYS 802112099, ISBN 82-518-0902-9

Johansen OE (1976)
Naturfag i skolen: noen fagdidaktiske synspunkter
Tanum-Norli, Oslo, 212 s.
BIBSYS 89200939x, ISBN 82-518-0494-9

Christensen KG, Johansen OE, Rudberg B (1972)
Selvinstruerende innføring i elementær mengdelære
Aschehoug, [Oslo], 102 s.
BIBSYS 783005679, ISBN 82-03-04877-3

Christensen KG, Johansen OE, Rudberg B (1972)
Matematikk for lærerutdanning
Aschehoug, Oslo, 227 s.
BIBSYS 783005660, ISBN 82-03-05067-0

Christensen KG, Johansen OE, Rudberg B (1972)
Begreper fra elementær mengdelære: En selvinstruerende innføring
Aschehoug, Oslo, Bl.29+upg.s.
BIBSYS 960610553, ISBN 82-03-05201-0

Christensen KG, Johansen OE, Rudberg B (1971)
Ny matematikk for lærerutdanning
Aschehoug, [Oslo]
BIBSYS 890218803

Book chapters

Johansen OE, Birkeland KI (2003)
Preventing macrovascular disease in patients with type 2 diabetes mellitus
In American journal of cardiovascular pathology, Field & Woods, Philadelphia, 3(2003)4, s.283-97
BIBSYS 041719182

Theses

Johansen OE (2007)
Cardiovascular disease and type 2 diabetes - a multifaceted symbiosis
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 496, 1 b. (flere pag.)
BIBSYS 070698295, ISBN 978-82-8072-861-6

Johansen OE (1963)
Noen resultater fra demrings- og nordlysspektre observertmed fotoelektrisk spektrometer
O.E. Johansen, Oslo, 71 s.
BIBSYS 971358257